传统PCI
医学
心脏病学
内科学
左主干冠状动脉疾病
冠状动脉疾病
入射(几何)
心肌梗塞
经皮冠状动脉介入治疗
冠心病
死因
动脉
冠心病
左冠状动脉
疾病
作者
Luca Testa,J M De La Torre Hernandez,Giovanni Luigi De Maria,Daniel A. Jones,Pablo Piñón-Esteban,Gianluca Campo,Bruno García del Blanco,Manuel Pan,Tamara García-Camarero,Gennaro Sardella,Peter O’Kane,J Greenwood,F Ribichini,Irene Pescetelli,Alfonso Ielasi,Íñigo Lozano,James Cockburn,Jacopo Oreglia,Azfar G. Zaman,Francesco Bedogni
标识
DOI:10.1056/nejmoa2600440
摘要
BACKGROUND: Percutaneous coronary intervention (PCI) is increasingly used for revascularization of unprotected left main coronary artery disease. Whether intravascular ultrasonographic (IVUS) guidance during PCI results in better clinical outcomes than conventional angiographic guidance alone is uncertain. METHODS: In an international, multicenter, open-label trial, we randomly assigned patients with unprotected left main coronary artery disease in a 1:1 ratio to undergo either IVUS-guided PCI or angiography-guided PCI. The primary end point was a patient-oriented composite of any stroke, any myocardial infarction, any revascularization, or death from any cause at the longest follow-up. RESULTS: A total of 806 patients underwent randomization; 401 were assigned to undergo IVUS-guided PCI and 405 to undergo angiography-guided PCI. The mean (±SD) age of the patients was 71.4±10.7 years, 78.4% of the patients were men, and 34.7% had diabetes. At a median follow-up of 2.9 years, a primary end-point event had occurred in 135 patients (33.7%) in the IVUS-guided PCI group and in 125 patients (30.9%) in the angiography-guided PCI group (hazard ratio, 1.11; 95% confidence interval, 0.87 to 1.42; P = 0.40). The incidence of death, myocardial infarction, or revascularization appeared to be similar in the two groups. The percentages of patients with procedure-related and overall safety events also appeared to be similar in the two groups. CONCLUSIONS: Among patients with unprotected left main coronary artery disease, IVUS-guided PCI showed no additional benefit over angiography-guided PCI with respect to the incidence of stroke, myocardial infarction, any revascularization, or death from any cause at a median follow-up of 2.9 years. (Funded by Philips Image Guided Therapy Devices and Boston Scientific; OPTIMAL ClinicalTrials.gov number, NCT04111770.).
科研通智能强力驱动
Strongly Powered by AbleSci AI